Director/PDMR Shareholding

RNS Number : 4488J
Epistem Holdings plc
30 June 2011
 



Epistem Holdings Plc ("Epistem" or the "Company")

 

 

Directors' Shareholdings

 

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009, and the sale of 2,175 ordinary shares of 1.5p each by a charitable trust of which a Director of the Company is a beneficiary.

 

 

As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors each increased their beneficial interests in the Company by 198 ordinary shares of 1.5p each. These shares were acquired on 1 April 2011, 11 April 2011, 10 June 2011 and 20 June 2011 at prices of 380p, 378p, 384p and 388p respectively.

 

Epistem was also notified on 29 June 2011 that earlier that day the Jeffrey G. Moore Charitable Remainder Unitrust, a U.S. based trust in which Dr. Jeffrey Moore, a Director of the Company, is a beneficiary, has been required under its trust rules to sell 15% of its aggregate holding and has therefore sold 2,175 ordinary shares of 1.5p each at a price of 369.75p per share.

 

Following these transactions, the current beneficial interests of the executive Directors are set out below:

 

 

Matthew Walls

8,377

(0.11%)

Dr Catherine Booth

982,732

(12.39%)

Dr Ged Brady

2,732

(0.03%)

Dr Jeffrey Moore

15,057

(0.19%)

John Rylands

192,630

(2.43%)

 

 

 

 

For further details please contact:

 

Epistem Plc

 

Matthew Walls, CEO

+44 161 606 7258

John Rylands, Finance Director

+44 161 606 7244

 

 

Peel Hunt LLP

 

James Steel / Vijay Barathan

+44 20 7418 8900

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGCGDLIGXBGBG

Companies

Genedrive (GDR)
UK 100

Latest directors dealings